A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: A Gynecologic Oncology Group study

被引：3
|
作者：
Landrum, L. M. [1 ]
Brady, W. E. [2 ]
Armstrong, D. K. [3 ]
Moore, K. N. [1 ]
DiSilvestro, P. A. [4 ]
O'Malley, D. M. [5 ]
Tenney, M. E. [6 ]
Rose, P. G. [7 ]
Fracasso, P. M. [8 ]
机构：
[1] Univ Oklahoma, Oklahoma City, OK USA
[2] Gynecol Oncol Grp Stat & Data Ctr, Buffalo, NY USA
[3] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA
[4] Brown Univ, Women & Infants Hosp, Providence, RI USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Univ Chicago, Chicago, IL 60637 USA
[7] Cleveland Clin, Cleveland, OH 44106 USA
[8] Univ Virginia, Charlottesville, VA USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 137卷
关键词：
D O I：
10.1016/j.ygyno.2015.01.053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
51
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An JNRG Oncology/Gynecologic Oncology Group study
    Landrum, Lisa M.
    Brady, William E.
    Armstrong, Deborah K.
    Moore, Kathleen N.
    DiSilvestro, Paul A.
    O'Malley, David M.
    Tenney, Meaghan E.
    Rose, Peter G.
    Fracasso, Paula M.
    GYNECOLOGIC ONCOLOGY, 2016, 140 (02) : 204 - 209
  • [2] A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
    del Carmen, Marcela G.
    Micha, John
    Small, Laurie
    Street, Daron G.
    Londhe, Anil
    McGowan, Tracy
    GYNECOLOGIC ONCOLOGY, 2012, 126 (03) : 369 - 374
  • [3] A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer
    Nakanishi, Toru
    Aoki, Daisuke
    Watanabe, Yoh
    Ando, Yuichi
    Tomotsugu, Naoki
    Sato, Yuji
    Saito, Toshiaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (05) : 422 - 426
  • [4] Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers
    Pothuri, B.
    Sparano, J.
    Blank, S.
    Curtin, J.
    Chuang, E.
    Hershman, D.
    Tiersten, A.
    Liebes, L.
    Chen, A.
    Muggia, F.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S22 - S22
  • [5] Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).
    Martin, Lainie P.
    Jain, Angela
    Chu, Christina
    Mantia-Smaldone, Gina
    Rubin, Stephen C.
    Ross, Eric A.
    Schilder, Russell J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study.
    del Carmen, M. G.
    Micha, J. P.
    Small, L. A.
    Street, D. G.
    Londhe, A.
    McGowan, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] A single-arm study of carboplatin and pegylated liposomal doxorubicin plus bevacizumab in subjects with platinum-sensitive recurrent ovarian, fallopian tube and primary peritoneal cancers: An interim safety analysis
    Del Carmen, M.
    Lowery, C.
    Micha, J.
    Small, L.
    Street, D.
    Lantz, K.
    Londhe, A.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S124 - S125
  • [8] Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group
    Rose, Peter G.
    Greer, Benjamin E.
    Horowitz, Ira R.
    Markman, Maurie
    Fusco, Nancy
    GYNECOLOGIC ONCOLOGY, 2007, 104 (01) : 114 - 119
  • [9] Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
    Jelovac, D.
    Armstrong, D. K.
    Weil, S.
    Phillips, M.
    Schwartz, B. M.
    Estes, J. M.
    Alvarez, R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC)
    Kim, Kenneth H.
    Jelovac, Danijela
    Armstrong, Deborah Kay
    Weil, Susan
    Phillips, Martin
    Schwartz, Benjamin M.
    Estes, Jacob Michael
    Alvarez, Ronald David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345